Элсульфавирин натрия

Quick links

Choose a section

Quick links to important sections

Advertisements

Элсульфавирин натрия

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Элсульфавирин натрия

Quick Facts

Property Description
Active ingredient Elsulfavirine (INN), formulated as the sodium salt
Form Oral Capsule (Single-ingredient product)
Pharmacological Class Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
General Purpose Disruption of viral replication in persistent infections
Origin Synthetic small molecule

Элсульфавирин натрия: Definition and Pharmacological Classification

Элсульфавирин натрия is a specialized, synthetic small molecule drug classified as a direct-acting antiviral agent intended for systemic use. The compound, known by the International Nonproprietary Name (INN) elsulfavirine, belongs to the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) pharmacological group. This classification is documented under the Anatomical Therapeutic Chemical (ATC) code J05AG07. The compound exhibits high selectivity in inhibiting its target enzyme. This new-generation status differentiates it within the NNRTI class, reflecting its development for targeted efficacy.

What is the Composition and Form of Элсульфавирин натрия?

The medication is a single-ingredient product where Элсульфавирин натрия functions as a prodrug—an inactive compound administered to generate the active therapeutic substance, deselsulfavirine, upon absorption. It is available as an oral formulation presented in a capsule for patient use, confirming its oral route of administration. The compound is structured as the sodium salt of the active moiety, a chemical formulation used to ensure optimal stability and absorption. The prodrug strategy is a method used in drug design to enhance effective delivery of the active component.

What is the General Therapeutic Purpose of Elsulfavirine?

The general therapeutic purpose of elsulfavirine is to serve as a critical component of antiretroviral therapy, aimed at maintaining long-term control over chronic viral replication. Its high-level function is the precise reverse transcriptase inhibition of the target viral enzyme. This selective mechanism prevents the fundamental process of viral replication, which is the necessary objective for achieving effective control of the persistent viral infection. The medicine is typically prescribed for patients initiating this type of specialized therapy.

Advertisements

What side effects are possible with Элсульфавирин натрия?

Possible Side Effects and Safety Information

The safety profile of elsulfavirine is documented by government regulatory authorities, classifying adverse reactions based on frequency and the body system affected. This classification is consistent with the standards for Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs).

Official Classification of Adverse Reactions

The most frequently observed effects are categorized as Common (occurring in ge 1/100 to < 1/10 treated patients), primarily involving the Nervous System and Gastrointestinal Disorders, as noted in regulatory summaries.

System Organ Class Common Adverse Reactions
Nervous System Disorders Headache, Dizziness, Insomnia
Gastrointestinal Disorders Nausea, Abdominal discomfort, Diarrhea, Vomiting
Skin Disorders Rash (Skin rash)
General Disorders Fatigue, Asthenia

Reactions classified as Uncommon include certain hypersensitivity reactions and documented increases in liver enzymes (transaminases), which fall under Hepatobiliary disorders.

Serious Safety Patterns and Constraints

Serious adverse reactions cited in regulatory documents include Severe Cutaneous Reactions, such as Stevens-Johnson syndrome, and systemic hypersensitivity. These reactions represent the highest tier of safety concern, though they are rare events.

Certain effects are noted as time-specific: Rash is typically observed during the first 4–6 weeks of treatment, and monitoring for elevated liver enzymes is relevant during the initial phase of therapy. Safety constraints are also defined for specific patient profiles. For example, use is generally contraindicated or not recommended in individuals with severe hepatic impairment, and caution is noted for older adults.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Элсульфавирин натрия (elsulfavirine) defines the overdose profile primarily through mandated emergency actions and procedural management.

Documented Presentations and Emergency Response

The available official prescribing information does not formally detail specific clinical signs, symptoms, or physiological findings that are uniquely attributable to an overdose of the compound. Due to this non-specific profile, regulatory authorities universally mandate that patients seek immediate medical attention and contact emergency services upon known or suspected overexposure. This strict requirement ensures prompt medical evaluation regardless of the presence or absence of initial symptoms. No population-specific differences in overdose severity or management are formally documented in the available official regulatory text.

Supportive Care and Observation

The official label confirms that no specific antidote is known for Элсульфавирин натрия. Consequently, management of the overdose is required to be strictly symptomatic and supportive, focusing on addressing the patient’s immediate clinical condition and maintaining stability. The mandated procedure requires close medical observation and continuous monitoring of vital signs as part of the official management protocol. This approach ensures that any clinical manifestations resulting from the overdose are managed according to strict regulatory guidelines, emphasizing the seriousness of any overexposure event.

Advertisements

Therapeutic Uses of Элсульфавирин натрия

What Элсульфавирин натрия Treats: Main Uses and Benefits

The role of Элсульфавирин натрия is generally to serve as an important component in the long-term management of chronic viral infection, focusing on sustained control of the underlying disease rather than episodic symptom relief. As part of combination antiretroviral therapy (cART), its core purpose aligns with the universal goals of HIV treatment.

This medication is primarily relevant for managing the underlying condition of HIV-1 infection in adults, particularly as a foundational agent in first-line therapy. The main therapeutic focus is to manage and support viral suppression, which helps ease the overall symptom burden by managing the symptoms related to systemic imbalance caused by viral activity. By assisting with managing viral replication, the drug supports the body's immune defenses to recover, a process that contributes to stability. This immunologic restoration supports the body's resistance to symptoms of progressive immunodeficiency.

“A main benefit of this therapy involves the sustained control of the virus, which supports the process of maintaining stability in the long term.”

Property Description
Quick Fact: Therapeutic Focus Managing and supporting sustained viral suppression in chronic infection.
Quick Fact: Patient Benefit Supports immune recovery and helps ease the overall symptom burden linked to systemic imbalance.

Regulatory References

  1. NIH Clinical Guidelines on Optimizing ARV Therapy
Advertisements

Eligibility and Restrictions for Use

Eligibility for Use: Official Regulatory Information

The eligibility profile for Elsulfavirine (Элсульфавирин натрия) is strictly defined by regulatory authorities based on age, reproductive status, organ function, and specific pre-existing medical conditions. The medicine is authorized for use only in adult patients (18 years and older) with HIV-1 infection.

Category Regulatory Status
Absolute Contraindications Pediatric patients (under 18 years); Pregnant and lactating individuals; Patients with known hypersensitivity to any component; Patients with specific metabolic disorders (lactose intolerance or malabsorption).
Organ Function Exclusion Moderate to severe hepatic impairment (Child-Pugh Class B and C) and moderate to severe renal impairment (estimated GFR < 60 mL/min) are formal contraindications.

Conditional Use and Caution

Use is restricted and requires explicit caution and monitoring for specific groups, including geriatric patients (older adults) and those with mild hepatic impairment (Child-Pugh Class A). Caution is also required for patients with a history of chronic hepatitis or specific hematologic conditions like severe anemia and pancytopenia.

The overall regulatory structure establishes non-eligibility through absolute contraindications relating to age, reproductive state, and critical organ function thresholds.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Elsulfavirine is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. This metabolic pathway is the main basis for potential drug interactions, as co-administered products can alter the plasma concentration of Elsulfavirine.

CYP3A4 Inducers accelerate the metabolism of Elsulfavirine, leading to decreased plasma concentrations. This reduction in drug level may potentially compromise the antiviral efficacy of the treatment. Known inducers include specific agents like Rifampin, Carbamazepine, and the herbal supplement St. John's Wort.

Conversely, strong CYP3A4 Inhibitors slow down the metabolism of Elsulfavirine, resulting in increased plasma concentrations. Elevated levels may heighten the risk of adverse effects. Inhibitors include specific medicinal products such as Ketoconazole, Erythromycin, and certain Protease Inhibitors.

Additionally, co-administration with Antacids and other gastrointestinal agents may affect the overall absorption of Elsulfavirine. To minimize this risk of an absorption-related interaction, official regulatory guidance advises separating the administration of Elsulfavirine from these gastrointestinal agents by at least a few hours. These interaction considerations are critical in the context of combination antiretroviral therapy.

Advertisements

Mechanism of Action

The mechanism of action of Элсульфавирин натрия is initiated by its function as a prodrug. Upon absorption, it undergoes rapid metabolism, converting into the pharmacologically active metabolite, VM-1500A. This active agent exerts its primary effect by targeting the Reverse Transcriptase (RT) enzyme of HIV-1. VM-1500A is classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). It binds specifically to an allosteric site on the RT enzyme, inducing a conformational change in the enzyme's structure. This structural modification prevents the enzyme from synthesizing viral DNA from its RNA template. By blocking this molecular cascade, the drug interrupts a core step in the viral replication cycle. Additionally, the active metabolite engages in a secondary, non-antiviral mechanism involving a reversible interaction with Carbonic Anhydrase within red blood cells. This interaction acts as a pharmacokinetic modulator, creating a temporary depot that slowly releases the drug back into the plasma. This physicochemical feature contributes to a prolonged drug half-life, which results in sustained plasma concentrations.

Advertisements

Dosage and Administration Information

How to Use Elsulfavirine Sodium: Official Administration Guidelines

Elsulfavirine sodium is a new-generation antiretroviral agent intended for long-term, systemic administration.


Administration Scope

Field Instruction
Route of administration Oral route only, supplied in a capsule formulation.
Dosing schedule (Adults) The recommended standard adult dose is 20 mg.
Timing in relation to meals The dose should be taken 15 minutes before meals.
Age-group administration rules The standard regimen is established for use in adults.
Special procedural conditions Must be administered in combination with other antiretroviral drugs as part of a comprehensive therapy regimen.

Instruction Classifications (High-Level)

Field Classification
Administration method type Oral (by mouth).
Frequency pattern Once Daily (QD) administration.
Use-context constraints Mandatory use as a component of combination antiretroviral therapy (cART).

Resulting Procedural Structure

The approved usage protocol defines a sequence for consistent intake.

Official step sequence:

  • The patient takes the prescribed 20 mg oral capsule.
  • The dose is ingested once per day.
  • The administration must occur specifically 15 minutes prior to a meal to meet label-based timing requirements.
  • The full regimen requires concurrent use with two or more other antiretroviral agents to form a complete combination therapy.

The official instructions establish a fixed 20 mg dose with a mandatory once-daily frequency and a strict requirement for pre-meal timing. This procedural framework ensures the medicine is consistently incorporated into a patient's continuous, long-term combination therapy protocol.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Элсульфавирин натрия


Evidence for Use in First-Line HIV-1 Treatment

The primary research for Elsulfavirine (Элсульфавирин натрия) was evaluated in studies involving adult patients with HIV-1 infection, typically as a component of an initial combination antiretroviral regimen for ART-naïve individuals. The research design involved randomized, controlled, multicenter trials. These trials were observed in study participants over defined time intervals to gather data on patterns measured in relation to the study regimen on key physiological markers.

The studies monitored outcomes related to virologic biomarkers, such as changes in the levels of the HIV-1 virus (RNA) in the blood. They also examined outcomes related to immunologic biomarkers, specifically changes in the count of CD4+ T-cells and the CD4/CD8 ratio, which are used in research to reflect outcomes monitoring physiological strain or stress. These findings show patterns related to changes in these markers observed in the studies over the duration of the trials.


Study Design and Comparators Used in Trials

The core research was conducted in comparative trials, meaning they were evaluated in populations where patients received either Elsulfavirine combined with other agents or a standard regimen based on a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI). This comparison was evaluated in comparison with an existing treatment option.

The initial follow-up periods used in the main regulatory trials were intermediate-term, tracking outcomes up to 48 weeks. The study results describe patterns related to viral and immunologic markers observed during the comparison against the control treatment over that time interval.


Long-Term Data and Follow-Up Duration

While the pivotal studies focused on intermediate outcomes, patients who completed the initial trials were observed in subsequent open-label extension studies. These extensions were designed to track data for long-term outcomes, with observations extending up to 96 or 100 weeks. This longer follow-up research explored the durations of the measured changes in the specific populations studied.


Key Research Gaps and Uncertainties

The primary research and subsequent regulatory approval were derived from specific Eurasian jurisdictions, meaning there is limited information available from major global health authorities, such as the FDA or EMA, who have not completed their own reviews.

Furthermore, while the research was conducted in comparative settings, the comparison was structured primarily against another established NNRTI. Lastly, the long-term outcomes are not fully established, as the post-authorization studies, designed to collect broad, real-world data over many years, are ongoing. These limitations highlight what is known — and what is still uncertain — about the drug's use outside of the controlled conditions under which the initial study results were obtained.

Key Studies & References

  1. Elsulfavirine-based Antiretroviral Treatment in Combination with Two NRTIs: 96 Weeks (Presentation of extension data)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Элсульфавирин натрия (FAQ)


Q: В чем основное отличие Элсульфавирин натрия от других лекарств в этой группе?

A: This medicine is classified as a newer generation Non-nucleoside Reverse Transcriptase Inhibitor ( NNRTI). Official information notes that it functions as a prodrug—an inactive compound that is converted into the active drug in the body. Its structure is noted for exhibiting a prolonged half-life, a pharmacological property that distinguishes it from some older NNRTIs.


Q: Какой эффект можно ожидать от Элсульфавирин натрия?

A: The intended effect of the therapy is the long-term control of the HIV-1 virus. Studies examined key outcomes related to a reduction in the amount of virus in the blood (viral load). Evidence also shows a monitoring pattern related to the recovery of the immune system, measured by an increase in CD4+ cell counts.


Q: Сколько времени обычно длится курс лечения Элсульфавирин натрия?

A: Official guidance states that this medication is intended for long-term, systemic administration. Treatment for the underlying chronic viral infection is typically continuous. Therefore, this medicine is defined as a component of combination antiretroviral therapy ( cART) intended for continuous, long-term administration.


Q: Правда ли, что Элсульфавирин натрия может вызывать сонливость?

A: The regulatory product information commonly lists dizziness and insomnia (difficulty sleeping) as side effects affecting the nervous system. Although drowsiness ( somnolence) may not be explicitly listed, similar CNS effects have been observed with medicines in this pharmacological class.


Q: Может ли Элсульфавирин натрия влиять на способность управлять автомобилем?

A: Official warnings state that due to common central nervous system effects, there is a risk of impaired ability to drive or operate machinery. This risk is associated with side effects like dizziness and headache.


Q: Есть ли известные взаимодействия Элсульфавирин натрия с витаминами или БАДами?

A: The label information indicates that using the herbal supplement St. John’s Wort ( зверобой) is generally contraindicated because it can significantly decrease the level of the drug in the body, potentially reducing its effect. Regulatory guidance emphasizes consulting a healthcare provider regarding all supplements being taken.


Q: Если у меня аллергия на другие лекарства, могу ли я принимать Элсульфавирин натрия?

A: Official guidance states that the medicine is strictly contraindicated if a patient has a known hypersensitivity or allergy to any of its active or inactive components. Regulatory documentation notes that caution should be used if there is a history of generalized severe allergies or hypersensitivity reactions to other drugs.


Q: Правда ли, что препарат Элсульфавирин натрия внесен в какие-то международные протоколы лечения?

A: This medicine has received regulatory approval and is included in treatment protocols within the Eurasian economic space where it is authorized. Official information also notes that major global health authorities, such as the FDA or the EMA, have not finalized their reviews for inclusion in their specific protocols.


Q: Нужно ли сдавать какие-то анализы до начала приема Элсульфавирин натрия?

A: Yes. Regulatory requirements for this medicine necessitate that blood tests checking the status of your liver and kidney function are performed prior to initiating therapy. These baseline results are used to ensure the medicine is appropriate, as severe organ impairment is a formal contraindication.


Q: Как долго после прекращения приема Элсульфавирин натрия он остается в организме?

A: Studies describing the medicine’s pharmacological properties note that it has a prolonged half-life. This is because its unique mechanism includes a depot effect that slows down how quickly the active component is cleared from the body. Consequently, the drug remains at detectable levels for an extended period after the last dose is taken.


Q: Каковы признаки того, что Элсульфавирин натрия начал работать?

A: Studies indicate that the primary markers for confirmation that the medicine is working are obtained through follow-up laboratory tests, which monitor virologic and immunologic progress. These tests look for a specific decrease in the amount of HIV-1 virus ( RNA) in the blood and an increase in immune CD4+ cell counts.


Q: Почему врачи назначают Элсульфавирин натрия вместо других лекарств?

A: The decision to prescribe this medicine is based on its specific pharmacological properties relative to other treatments in its class. Official sources highlight that it is a new-generation NNRTI with a prodrug design and a prolonged half-life. These pharmacological features are noted as key considerations for prescribers when selecting a continuous, long-term therapy regimen.


Q: Влияет ли Элсульфавирин натрия на общее самочувствие и настроение?

A: Yes, the medicine can affect general well-being and mood. Side effects commonly listed include fatigue, asthenia (lack of energy), insomnia, and headache. Regulatory documents also note that mood changes, such as anxiety, have been observed with medicines belonging to the NNRTI pharmacological class.


Q: Почему Элсульфавирин натрия не продается без рецепта?

A: This medicine is designated as a prescription-only ( Rx) drug. It is used as part of a complex combination therapy for a serious, chronic condition and requires close medical supervision. Its use requires careful assessment against strict eligibility and organ function criteria, which necessitates a prescription.


Q: Есть ли риск, что Элсульфавирин натрия перестанет работать со временем?

A: Yes, studies and regulatory requirements confirm a risk of the HIV-1 virus developing resistance to the medicine over time. This is the primary reason why it is mandatory to take this drug only as a component of a combination antiretroviral therapy ( cART) regimen, which is the standard protocol designed to prevent viral adaptation.


Q: Может ли Элсульфавирин натрия помочь при других заболеваниях, кроме основных?

A: Official regulatory documents state that this medicine is approved and indicated only for the treatment of HIV-1 infection in adult patients. Information concerning its use for any other medical conditions or diseases is not included in the regulatory label.


Q: Существует ли риск развития привыкания к Элсульфавирин натрия?

A: Official regulatory documents do not contain any specific warnings, notes, or classifications indicating a risk of physical dependence, abuse, or habituation associated with the use of this medicine.


Q: Что делать, если пропустил(а) прием Элсульфавирин натрия?

A: The official guidance for managing a missed dose generally advises that the dose may be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose. If the next dose is due shortly, the missed dose is typically skipped. It is strictly stated in the product information that a double dose should never be taken.


Q: Безопасно ли сочетать Элсульфавирин натрия с приемом алкоголя?

A: The regulatory warnings do not state a formal contraindication or specific interaction with alcohol. However, due to the medicine’s potential to cause CNS side effects such as dizziness, fatigue, and headache, the regulatory information suggests that alcohol consumption should be approached with caution, as it may potentially worsen these effects.


Q: Может ли Элсульфавирин натрия изменить результаты лабораторных тестов?

A: Yes. Regulatory safety summaries indicate that the medicine can cause certain changes in laboratory values. These changes include transient increases in liver enzyme levels ( transaminases) and expected changes in immune cell ( CD4+) counts, both of which are monitored during the course of therapy.


Q: Влияет ли Элсульфавирин натрия на кровяное давление?

A: Specific changes related to blood pressure, such as hypertension or hypotension, are not listed among the commonly or uncommonly reported side effects in the regulatory product summaries for this medicine.


Q: Является ли Элсульфавирин натрия рецептурным препаратом?

A: Yes, this medicine is classified as a prescription-only ( Rx) drug. This status is standard for medicines that are part of a complex, monitored, combination therapy regimen.


Q: Что делать, если побочные эффекты от Элсульфавирин натрия не проходят?

A: The patient information states that if you experience any side effects that are severe, worsen over time, or do not go away, you should seek guidance. Regulatory guidance emphasizes the importance of reporting persistent or concerning symptoms to a healthcare professional, as they are best positioned to provide necessary evaluation.


Q: Есть ли ограничения по диете во время приема Элсульфавирин натрия?

A: Regulatory documents do not list any specific restrictions on the content of your diet while taking this medicine. The only official requirement regarding food is the timing of administration, which is specified as 15 minutes before a meal to promote optimal absorption.


Q: Влияет ли Элсульфавирин натрия на эффективность противозачаточных средств?

A: Yes. Regulatory warnings state that due to a potential drug interaction, hormonal contraceptives (like birth control pills or patches) may become less effective. Official warnings recommend the use of a reliable barrier method of contraception in conjunction with hormonal methods due to the risk of reduced effectiveness.


Q: Может ли прием Элсульфавирин натрия вызвать набор веса?

A: Changes in body weight, including weight gain, are not listed among the commonly or uncommonly reported side effects in the official regulatory summaries for this medicine.


Q: Может ли Элсульфавирин натрия взаимодействовать с грейпфрутовым соком?

A: Yes. Grapefruit juice is noted as a strong inhibitor of the CYP3 A4 enzyme, which is responsible for breaking down this medicine. Due to this risk, the consumption of grapefruit juice is generally advised against in official regulatory warnings.

Advertisements

How should Элсульфавирин натрия be stored and disposed of?

How to Store and Dispose of Elsulfavirine Sodium (Элсульфавирин натрия)

Storage and disposal requirements for Elsulfavirine sodium capsules are strictly defined in the official regulatory labeling to maintain product quality and ensure safety.

Official Storage Conditions

Requirement Official Regulatory Statement
Maximum Temperature Store at a temperature not higher than 25 °C.
Protection Must be stored in a place protected from light.
Shelf Life The official shelf life is 2 years; do not use after the expiration date.
Child Safety Must be kept out of the sight and reach of children.

Disposal

The standard regulatory instructions do not specify a unique disposal procedure. Unused or expired medication must be discarded according to established local regulations for pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Элсульфавирин натрия found in:

A-Z Index: